These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8549307)

  • 21. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
    Scheen AJ
    Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levofloxacin in patients with severe respiratory tract infection.
    Odagiri S
    Drugs; 1995; 49 Suppl 2():426-7. PubMed ID: 8549387
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.
    Kawai T
    Drugs; 1995; 49 Suppl 2():416-7. PubMed ID: 8549383
    [No Abstract]   [Full Text] [Related]  

  • 24. [In vitro activity of 3 fluoroquinolones on Branhamella catarrhalis].
    Suermondt G; Denamur E; Laurans G; Orfila J
    Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):647-50. PubMed ID: 3141885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
    Rubinstein E
    J Antimicrob Chemother; 2003 May; 51(5):1307-8; author reply 1308-9. PubMed ID: 12697636
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections.
    Sato A; Ogawa H; Iwata M; Ono T; Yasuda K; Nagayama M; Shirai T; Shirai M; Ida M; Suda T
    Drugs; 1995; 49 Suppl 2():428-9. PubMed ID: 8549388
    [No Abstract]   [Full Text] [Related]  

  • 27. [Fluoroquinolones in respiratory infections].
    Mouton Y; Leroy O
    Presse Med; 1994 Nov; 23(35):1616-20. PubMed ID: 7831243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levofloxacin.
    Norrby SR
    Expert Opin Pharmacother; 1999 Nov; 1(1):109-19. PubMed ID: 11249554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
    Yamaguchi K; Miyazaki S; Kashitani F; Iwata M; Kanda M; Tsujio Y; Okada J; Tazawa Y; Watanabe N; Uehara N; Igari J; Oguri T; Kaimori M; Kawamura C; Iinuma Y; Nisawataira T; Tashiro H; Ueno K; Ishigo S; Yasujima M; Kawahara S; Itoh C; Yoshida T; Yamanaka K; Toyoshima S; Katoh J; Kudoh M; Matsushima T; Niki Y; Miyashita N; Funato T; Kaku M; Sato N; Saito Y; Ishii K; Kuwabara M; Hongo T; Negayama K; Kamihira S; Miyazaki Y; Takii M; Ishii M; Nakagawa K; Ono J; Takada T; Murakami N; Taira M; Tamaki I; Matsudou Y; Nakasone I
    Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes.
    Tillotson G; Zhao X; Drlica K
    Lancet Infect Dis; 2001 Oct; 1(3):145-6. PubMed ID: 11871490
    [No Abstract]   [Full Text] [Related]  

  • 32. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
    Nakamori Y; Miyashita Y; Nakatani I; Nakata K
    Drugs; 1995; 49 Suppl 2():418-9. PubMed ID: 8549384
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.
    Shishido H; Furukawa K; Nagai H; Kawakami K; Kono H
    Drugs; 1995; 49 Suppl 2():433-5. PubMed ID: 8549391
    [No Abstract]   [Full Text] [Related]  

  • 34. [Levofloxacin: role and place in the treatment of infections of the lower respiratory tracts].
    Sinopal'nikov AI; Romanovskiĭ AG
    Ter Arkh; 2004; 76(11):51-6. PubMed ID: 15658538
    [No Abstract]   [Full Text] [Related]  

  • 35. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Davidson R; Cavalcanti R; Brunton JL; Bast DJ; de Azavedo JC; Kibsey P; Fleming C; Low DE
    N Engl J Med; 2002 Mar; 346(10):747-50. PubMed ID: 11882730
    [No Abstract]   [Full Text] [Related]  

  • 36. Levofloxacin, a second-generation fluoroquinolone.
    North DS; Fish DN; Redington JJ
    Pharmacotherapy; 1998; 18(5):915-35. PubMed ID: 9758306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical role of the quinolones today and in the future.
    Waldvogel FA
    Eur J Clin Microbiol Infect Dis; 1989 Dec; 8(12):1075-9. PubMed ID: 2620674
    [No Abstract]   [Full Text] [Related]  

  • 38. [The present and future of levofloxacin in the treatment of respiratory infections].
    García-Rodríguez JA; Muñoz Bellido JL; Alonso Manzanares MA; Gutiérrez Zufiaurre MN
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():53-8. PubMed ID: 10563113
    [No Abstract]   [Full Text] [Related]  

  • 39. [Respiratory tract infections. Increasingly more established antibiotics fail].
    MMW Fortschr Med; 2002 Oct; 144(42):65. PubMed ID: 12534005
    [No Abstract]   [Full Text] [Related]  

  • 40. [Treatment in general practice. Effective, well tolerated therapy].
    MMW Fortschr Med; 2000 Sep; 142(37):58-9. PubMed ID: 11026226
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.